Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer

Eriko Tokunaga, Satoko Okada, Hiroyuki Kitao, Satoko Shiotani, Hiroshi Saeki, Kazuya Endo, Masaru Morita, Yoshihiro Kakeji, Yoshihiko Maehara

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: The link between BRCA1 dysfunction and basal-like breast cancer or triple-negative breast cancer (TNBC) has been suggested; however, the associations of other factors involved in the Fanconi anemia (FA)/BRCA pathway with the pathogenesis of basal-like breast cancer remain unidentified. FANCF protein is a component of the FA core complex. The methylation of CpG islands in the FANCF gene plays an important role in occurrence of ovarian cancer and also is an important regulator of cisplatin sensitivity of ovarian cancer. The purpose of this study is to investigate the frequency of FANCF methylation, and to discuss its involvement in the pathogenesis of TNBC and its potency as a predictor of cisplatin sensitivity for breast cancer. Methods: The methylation of the FANCF gene promoter was investigated, using methylation-specific PCR, in genomic DNA of 99 invasive breast carcinoma specimens obtained from Japanese patients. Results: FANCF methylation was recognized in only 4 of 99 cases (4.0%). No significant correlation was found between FANCF methylation and the expression of ER, PR, HER2, and TNBC. Conclusions: FANCF methylation is a rare event in Japanese primary invasive breast cancer. This suggests it is not involved in the pathogenesis of TNBC, and it could not be used as a predictor of cisplatin sensitivity in breast cancer.

Original languageEnglish
Pages (from-to)120-123
Number of pages4
JournalBreast Cancer
Volume18
Issue number2
DOIs
Publication statusPublished - Apr 1 2011

Fingerprint

Genetic Promoter Regions
Methylation
Triple Negative Breast Neoplasms
Breast Neoplasms
Incidence
Genes
Cisplatin
Fanconi Anemia
Fanconi Anemia Complementation Group F Protein
Ovarian Neoplasms
CpG Islands
Polymerase Chain Reaction
DNA

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Cite this

Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer. / Tokunaga, Eriko; Okada, Satoko; Kitao, Hiroyuki; Shiotani, Satoko; Saeki, Hiroshi; Endo, Kazuya; Morita, Masaru; Kakeji, Yoshihiro; Maehara, Yoshihiko.

In: Breast Cancer, Vol. 18, No. 2, 01.04.2011, p. 120-123.

Research output: Contribution to journalArticle

Tokunaga, E, Okada, S, Kitao, H, Shiotani, S, Saeki, H, Endo, K, Morita, M, Kakeji, Y & Maehara, Y 2011, 'Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer', Breast Cancer, vol. 18, no. 2, pp. 120-123. https://doi.org/10.1007/s12282-009-0175-z
Tokunaga, Eriko ; Okada, Satoko ; Kitao, Hiroyuki ; Shiotani, Satoko ; Saeki, Hiroshi ; Endo, Kazuya ; Morita, Masaru ; Kakeji, Yoshihiro ; Maehara, Yoshihiko. / Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer. In: Breast Cancer. 2011 ; Vol. 18, No. 2. pp. 120-123.
@article{7080943ce4b243c394d11614da955a59,
title = "Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer",
abstract = "Purpose: The link between BRCA1 dysfunction and basal-like breast cancer or triple-negative breast cancer (TNBC) has been suggested; however, the associations of other factors involved in the Fanconi anemia (FA)/BRCA pathway with the pathogenesis of basal-like breast cancer remain unidentified. FANCF protein is a component of the FA core complex. The methylation of CpG islands in the FANCF gene plays an important role in occurrence of ovarian cancer and also is an important regulator of cisplatin sensitivity of ovarian cancer. The purpose of this study is to investigate the frequency of FANCF methylation, and to discuss its involvement in the pathogenesis of TNBC and its potency as a predictor of cisplatin sensitivity for breast cancer. Methods: The methylation of the FANCF gene promoter was investigated, using methylation-specific PCR, in genomic DNA of 99 invasive breast carcinoma specimens obtained from Japanese patients. Results: FANCF methylation was recognized in only 4 of 99 cases (4.0{\%}). No significant correlation was found between FANCF methylation and the expression of ER, PR, HER2, and TNBC. Conclusions: FANCF methylation is a rare event in Japanese primary invasive breast cancer. This suggests it is not involved in the pathogenesis of TNBC, and it could not be used as a predictor of cisplatin sensitivity in breast cancer.",
author = "Eriko Tokunaga and Satoko Okada and Hiroyuki Kitao and Satoko Shiotani and Hiroshi Saeki and Kazuya Endo and Masaru Morita and Yoshihiro Kakeji and Yoshihiko Maehara",
year = "2011",
month = "4",
day = "1",
doi = "10.1007/s12282-009-0175-z",
language = "English",
volume = "18",
pages = "120--123",
journal = "Breast Cancer",
issn = "1340-6868",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer

AU - Tokunaga, Eriko

AU - Okada, Satoko

AU - Kitao, Hiroyuki

AU - Shiotani, Satoko

AU - Saeki, Hiroshi

AU - Endo, Kazuya

AU - Morita, Masaru

AU - Kakeji, Yoshihiro

AU - Maehara, Yoshihiko

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Purpose: The link between BRCA1 dysfunction and basal-like breast cancer or triple-negative breast cancer (TNBC) has been suggested; however, the associations of other factors involved in the Fanconi anemia (FA)/BRCA pathway with the pathogenesis of basal-like breast cancer remain unidentified. FANCF protein is a component of the FA core complex. The methylation of CpG islands in the FANCF gene plays an important role in occurrence of ovarian cancer and also is an important regulator of cisplatin sensitivity of ovarian cancer. The purpose of this study is to investigate the frequency of FANCF methylation, and to discuss its involvement in the pathogenesis of TNBC and its potency as a predictor of cisplatin sensitivity for breast cancer. Methods: The methylation of the FANCF gene promoter was investigated, using methylation-specific PCR, in genomic DNA of 99 invasive breast carcinoma specimens obtained from Japanese patients. Results: FANCF methylation was recognized in only 4 of 99 cases (4.0%). No significant correlation was found between FANCF methylation and the expression of ER, PR, HER2, and TNBC. Conclusions: FANCF methylation is a rare event in Japanese primary invasive breast cancer. This suggests it is not involved in the pathogenesis of TNBC, and it could not be used as a predictor of cisplatin sensitivity in breast cancer.

AB - Purpose: The link between BRCA1 dysfunction and basal-like breast cancer or triple-negative breast cancer (TNBC) has been suggested; however, the associations of other factors involved in the Fanconi anemia (FA)/BRCA pathway with the pathogenesis of basal-like breast cancer remain unidentified. FANCF protein is a component of the FA core complex. The methylation of CpG islands in the FANCF gene plays an important role in occurrence of ovarian cancer and also is an important regulator of cisplatin sensitivity of ovarian cancer. The purpose of this study is to investigate the frequency of FANCF methylation, and to discuss its involvement in the pathogenesis of TNBC and its potency as a predictor of cisplatin sensitivity for breast cancer. Methods: The methylation of the FANCF gene promoter was investigated, using methylation-specific PCR, in genomic DNA of 99 invasive breast carcinoma specimens obtained from Japanese patients. Results: FANCF methylation was recognized in only 4 of 99 cases (4.0%). No significant correlation was found between FANCF methylation and the expression of ER, PR, HER2, and TNBC. Conclusions: FANCF methylation is a rare event in Japanese primary invasive breast cancer. This suggests it is not involved in the pathogenesis of TNBC, and it could not be used as a predictor of cisplatin sensitivity in breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=79956372634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956372634&partnerID=8YFLogxK

U2 - 10.1007/s12282-009-0175-z

DO - 10.1007/s12282-009-0175-z

M3 - Article

C2 - 19813073

AN - SCOPUS:79956372634

VL - 18

SP - 120

EP - 123

JO - Breast Cancer

JF - Breast Cancer

SN - 1340-6868

IS - 2

ER -